J
Judith G. Villablanca
Researcher at University of Southern California
Publications - 89
Citations - 8618
Judith G. Villablanca is an academic researcher from University of Southern California. The author has contributed to research in topics: Transplantation & Neuroblastoma. The author has an hindex of 38, co-authored 85 publications receiving 7774 citations. Previous affiliations of Judith G. Villablanca include Children's Hospital Los Angeles & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid
Katherine K. Matthay,Judith G. Villablanca,Seeger Rc,Daniel O. Stram,Richard E. Harris,Norma K.C. Ramsay,Patrick S. Swift,H. Shimada,C T Black,Garrett M. Brodeur,Robert B. Gerbing,C. P. Reynolds +11 more
TL;DR: Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with high-risk neuroblastoma, and treatment with 13-cis-retinoic acid was beneficial for patients without progressive disease when it was administered after chemotherapy or transplantation.
Journal ArticleDOI
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu,Andrew L. Gilman,M. Fevzi Ozkaynak,Wendy B. London,Susan G. Kreissman,Helen X. Chen,Malcolm A. Smith,Barry D. Anderson,Judith G. Villablanca,Katherine K. Matthay,H. Shimada,Stephan A. Grupp,Robert C. Seeger,C. Patrick Reynolds,Allen Buxton,Ralph A. Reisfeld,Steven D. Gillies,Susan L. Cohn,John M. Maris,Paul M. Sondel +19 more
TL;DR: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma.
Journal ArticleDOI
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay,C. Patrick Reynolds,Robert C. Seeger,Hiroyuki Shimada,E. Stanton Adkins,Daphne A. Haas-Kogan,Robert B. Gerbing,Wendy B. London,Judith G. Villablanca +8 more
TL;DR: The long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation or to receive chemotherapy, and subsequent treatment with 13-cis-retinoic acid (Cis-RA), was assessed.
Journal ArticleDOI
Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma
A. Linn Murphree,Judith G. Villablanca,William F. Deegan,Judith K. Sato,Marcio H. Malogolowkin,Anita M. R. Fisher,Ricardo J. Parker,Eddie Reed,Charles J. Gomer +8 more
TL;DR: Thermochemotherapy is successful primary treatment for Reese-Ellsworth group 1 and 2 retinoblastomas and external beam radiotherapy can safely be avoided in the primary treatment of Reese- Ellsworth groups 1 through 4 nondispersed retinOBlastoma.
Journal ArticleDOI
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study.
Casilda Balmaceda,Glenn Heller,Marc K. Rosenblum,Blanca Diez,Judith G. Villablanca,Stewart J. Kellie,P Maher,V Vlamis,Russell W. Walker,Steven A. Leibel,Jonathan L. Finlay +10 more
TL;DR: Chemotherapy-only regimens for CNS GCT, although encouraging, should continue to be used only in the setting of formal clinical trials.